EA201000506A1 - УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa - Google Patents

УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa

Info

Publication number
EA201000506A1
EA201000506A1 EA201000506A EA201000506A EA201000506A1 EA 201000506 A1 EA201000506 A1 EA 201000506A1 EA 201000506 A EA201000506 A EA 201000506A EA 201000506 A EA201000506 A EA 201000506A EA 201000506 A1 EA201000506 A1 EA 201000506A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
pharmaceutically acceptable
factor
urethanes
amides
Prior art date
Application number
EA201000506A
Other languages
English (en)
Other versions
EA015918B1 (ru
Inventor
Дмитрий Геннадьевич ТОВБИН
Дмитрий Николаевич ТАРАСОВ
Дмитрий Викторович МАЛАХОВ
Original Assignee
Дмитрий Геннадьевич ТОВБИН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дмитрий Геннадьевич ТОВБИН filed Critical Дмитрий Геннадьевич ТОВБИН
Priority to EA201000506A priority Critical patent/EA015918B1/ru
Priority to UAA201211358A priority patent/UA107106C2/ru
Priority to PT117509828T priority patent/PT2542529T/pt
Priority to SI201131816T priority patent/SI2542529T1/sl
Priority to NZ602769A priority patent/NZ602769A/en
Priority to LT11750982T priority patent/LT2542529T/lt
Priority to CN201180011928.4A priority patent/CN102971294B/zh
Priority to BR112012021884A priority patent/BR112012021884B8/pt
Priority to PCT/RU2011/000129 priority patent/WO2011108963A1/en
Priority to AU2011221601A priority patent/AU2011221601B2/en
Priority to HUE11750982A priority patent/HUE047249T2/hu
Priority to PL11750982T priority patent/PL2542529T3/pl
Priority to KR1020127025881A priority patent/KR101771760B1/ko
Priority to CA2791875A priority patent/CA2791875C/en
Priority to JP2012556036A priority patent/JP6078707B2/ja
Priority to DK11750982.8T priority patent/DK2542529T3/da
Priority to EP11750982.8A priority patent/EP2542529B1/en
Priority to MX2012009976A priority patent/MX2012009976A/es
Publication of EA201000506A1 publication Critical patent/EA201000506A1/ru
Publication of EA015918B1 publication Critical patent/EA015918B1/ru
Priority to US13/599,038 priority patent/US9708265B2/en
Priority to IL221727A priority patent/IL221727A/en
Priority to ZA2012/07345A priority patent/ZA201207345B/en
Priority to HK13109973.7A priority patent/HK1182700A1/xx
Priority to CY20191101032T priority patent/CY1122645T1/el
Priority to HRP20192125TT priority patent/HRP20192125T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Данное изобретение относится к новому классу соединений, их фармацевтически приемлемым солям и их фармацевтически приемлемым композициям, которые эффективны как селективные ингибиторы фактора Ха как в изолированном состоянии, так и в комплексе с другими белками. Новые соединения, описанные в изобретении, могут использоваться для лечения и профилактики болезней, таких как острый коронарный синдром, инфаркт миокарда, нестабильная стенокардия, рефракторная стенокардия, тромбозы, вызванные посттромболитической терапией или коронарной ангиопластикой, острый ишемический цереброваскулярный синдром, эмболический инсульт, тромботический инсульт и ряда других болезней у человека и млекопитающих, связанных со свертываемостью крови.
EA201000506A 2010-03-03 2010-03-03 УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa EA015918B1 (ru)

Priority Applications (24)

Application Number Priority Date Filing Date Title
EA201000506A EA015918B1 (ru) 2010-03-03 2010-03-03 УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
UAA201211358A UA107106C2 (uk) 2010-03-03 2011-02-03 УРЕТАНИ, СЕЧОВИНИ, АМІДИ ТА РОДИННІ ІНГІБІТОРИ ФАКТОРА Xа
PL11750982T PL2542529T3 (pl) 2010-03-03 2011-03-02 Uretany, moczniki, amidyny i powiązane inhibitory czynnika Xa
CA2791875A CA2791875C (en) 2010-03-03 2011-03-02 Urethanes, ureas, amidines and related inhibitors of factor xa
NZ602769A NZ602769A (en) 2010-03-03 2011-03-02 Urethanes, ureas, amidines and related inhibitors of factor xa
LT11750982T LT2542529T (lt) 2010-03-03 2011-03-02 Uretanai, karbamidai, amidinai ir faktoriaus xa giminingi inhibitoriai
CN201180011928.4A CN102971294B (zh) 2010-03-03 2011-03-02 氨基甲酸乙酯、尿素、脒和因子Xa的相关抑制剂
BR112012021884A BR112012021884B8 (pt) 2010-03-03 2011-03-02 Composto, composição farmacêutica e método para afetar a coagulação sanguínea ou coagulação de plasma sanguíneo
PCT/RU2011/000129 WO2011108963A1 (en) 2010-03-03 2011-03-02 Urethanes, ureas, amidines and related inhibitors of factor xa
AU2011221601A AU2011221601B2 (en) 2010-03-03 2011-03-02 Urethanes, ureas, amidines and related inhibitors of factor Xa
HUE11750982A HUE047249T2 (hu) 2010-03-03 2011-03-02 Uretánok, karbamidok, amidinek és rokon Xa faktor inhibitorok
PT117509828T PT2542529T (pt) 2010-03-03 2011-03-02 Uretanos, ureias, amidinas e inibidores relacionados do fator xa
KR1020127025881A KR101771760B1 (ko) 2010-03-03 2011-03-02 우레탄, 요소, 아미딘 및 관련된 Ｘａ 인자의 억제제
SI201131816T SI2542529T1 (sl) 2010-03-03 2011-03-02 Uretani, uree, amidini in sorodni inhibitorji faktorja Xa
JP2012556036A JP6078707B2 (ja) 2010-03-03 2011-03-02 第Ｘａ因子のウレタン、尿素、アミジン、及び関連阻害剤
DK11750982.8T DK2542529T3 (da) 2010-03-03 2011-03-02 Urethaner, urinstoffer, amidiner og relaterede inhibitorer af faktor xa
EP11750982.8A EP2542529B1 (en) 2010-03-03 2011-03-02 Urethanes, ureas, amidines and related inhibitors of factor xa
MX2012009976A MX2012009976A (es) 2010-03-03 2011-03-02 Uretanos, ureas, amidinas e inhibidores relacionados del factor xa.
US13/599,038 US9708265B2 (en) 2010-03-03 2012-08-30 Urethanes, ureas, amidines and related inhibitors of factor Xa
IL221727A IL221727A (en) 2010-03-03 2012-08-30 Compounds of urethane ureas, amidines and related inhibitors of factor xa, pharmaceutical preparations containing the compounds, use and method
ZA2012/07345A ZA201207345B (en) 2010-03-03 2012-10-01 Urethanes,ureas,amidines and related inhibitors of factor xa
HK13109973.7A HK1182700A1 (en) 2010-03-03 2013-08-26 Urethanes, ureas, amidines and related inhibitors of factor xa xa
CY20191101032T CY1122645T1 (el) 2010-03-03 2019-10-03 Oyρεθανες, ουριες, αμιδινες και σχετικοι αναστολεις του παραγοντα χα
HRP20192125TT HRP20192125T1 (hr) 2010-03-03 2019-11-26 URETANI, UREE, AMIDINI I POVEZANI INHIBITORI FAKTORA Xa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201000506A EA015918B1 (ru) 2010-03-03 2010-03-03 УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa

Publications (2)

Publication Number Publication Date
EA201000506A1 true EA201000506A1 (ru) 2011-10-31
EA015918B1 EA015918B1 (ru) 2011-12-30

Family

ID=44542428

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000506A EA015918B1 (ru) 2010-03-03 2010-03-03 УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa

Country Status (24)

Country Link
US (1) US9708265B2 (ru)
EP (1) EP2542529B1 (ru)
JP (1) JP6078707B2 (ru)
KR (1) KR101771760B1 (ru)
CN (1) CN102971294B (ru)
AU (1) AU2011221601B2 (ru)
BR (1) BR112012021884B8 (ru)
CA (1) CA2791875C (ru)
CY (1) CY1122645T1 (ru)
DK (1) DK2542529T3 (ru)
EA (1) EA015918B1 (ru)
HK (1) HK1182700A1 (ru)
HR (1) HRP20192125T1 (ru)
HU (1) HUE047249T2 (ru)
IL (1) IL221727A (ru)
LT (1) LT2542529T (ru)
MX (1) MX2012009976A (ru)
NZ (1) NZ602769A (ru)
PL (1) PL2542529T3 (ru)
PT (1) PT2542529T (ru)
SI (1) SI2542529T1 (ru)
UA (1) UA107106C2 (ru)
WO (1) WO2011108963A1 (ru)
ZA (1) ZA201207345B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017217895A1 (en) * 2016-06-15 2017-12-21 "Pharmadiall" Ltd Pharmaceutical compositions comprising anticoagulant n-(5-chloropyridine-2-yl)-2-({4-[ethanimidoil(methyl)amino]benzoyl}amino)-5-methylbenzamide

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014003153A1 (ja) * 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
RU2698202C2 (ru) * 2016-06-01 2019-08-23 Закрытое акционерное общество "ФАРМА ВАМ" СПОСОБ ПОЛУЧЕНИЯ ПРЯМОГО ИНГИБИТОРА ФАКТОРА Ха
RU2659161C1 (ru) 2017-11-17 2018-06-28 Общество С Ограниченной Ответственностью "Ива Фарм" Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид
EA201800084A1 (ru) * 2018-01-19 2019-07-31 Общество С Ограниченной Ответственностью "Фармадиол" НОВЫЕ АМИДИНЫ-ИНГИБИТОРЫ ФАКТОРА Ха

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
RU2154633C2 (ru) 1994-12-02 2000-08-20 Яманоути Фармасьютикал Ко., Лтд. Производные амидинонафтила и фармацевтическая композиция
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
EP0946508B1 (en) 1996-12-23 2009-09-23 Bristol-Myers Squibb Pharma Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
AU8747598A (en) 1997-08-27 1999-03-16 Kissei Pharmaceutical Co. Ltd. 3-amidinoaniline derivatives, activated blood coagulation factor x inhibitors, and intermediates for producing both
IL155155A0 (en) 1999-09-17 2003-10-31 Cor Therapeutics Inc BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
AU2108601A (en) * 1999-12-15 2001-06-25 Axys Pharmaceuticals, Inc. Salicylamides as serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE60115394T2 (de) * 2000-02-29 2006-10-19 Millennium Pharmaceuticals, Inc., Cambridge Benzamide und ähnliche inhibitoren vom faktor xa
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2002350217A1 (en) * 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
WO2006070878A1 (ja) * 2004-12-28 2006-07-06 Astellas Pharma Inc. カルボン酸誘導体またはその塩
DE102005042583A1 (de) * 2005-09-08 2007-03-15 Bayer Healthcare Ag Iminooxazolidin-Derivate und ihre Verwendung
NZ592533A (en) * 2005-11-08 2012-08-31 Millennium Pharm Inc METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
RU2452484C2 (ru) * 2006-12-08 2012-06-10 Милленниум Фармасьютикалз, Инк. Стандартные лекарственные препараты и способы лечения тромбоза пероральным введением ингибитора фактора ха

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017217895A1 (en) * 2016-06-15 2017-12-21 "Pharmadiall" Ltd Pharmaceutical compositions comprising anticoagulant n-(5-chloropyridine-2-yl)-2-({4-[ethanimidoil(methyl)amino]benzoyl}amino)-5-methylbenzamide

Also Published As

Publication number Publication date
WO2011108963A1 (en) 2011-09-09
HK1182700A1 (en) 2013-12-06
US20130005778A1 (en) 2013-01-03
BR112012021884B1 (pt) 2021-10-13
ZA201207345B (en) 2013-09-25
UA107106C2 (uk) 2014-11-25
HRP20192125T1 (hr) 2020-02-21
HUE047249T2 (hu) 2020-04-28
SI2542529T1 (sl) 2019-12-31
DK2542529T3 (da) 2019-10-07
WO2011108963A8 (en) 2012-12-27
EP2542529A1 (en) 2013-01-09
CN102971294B (zh) 2015-03-25
LT2542529T (lt) 2019-10-25
BR112012021884B8 (pt) 2021-12-28
CN102971294A (zh) 2013-03-13
CY1122645T1 (el) 2021-03-12
JP2013521278A (ja) 2013-06-10
NZ602769A (en) 2015-01-30
KR101771760B1 (ko) 2017-08-28
CA2791875A1 (en) 2011-09-09
JP6078707B2 (ja) 2017-02-15
BR112012021884A2 (pt) 2016-05-24
PL2542529T3 (pl) 2020-03-31
EA015918B1 (ru) 2011-12-30
AU2011221601A1 (en) 2012-10-25
EP2542529B1 (en) 2019-09-04
PT2542529T (pt) 2019-12-09
KR20130044222A (ko) 2013-05-02
AU2011221601B2 (en) 2016-10-27
EP2542529A4 (en) 2013-09-04
MX2012009976A (es) 2012-12-17
IL221727A (en) 2016-11-30
US9708265B2 (en) 2017-07-18
CA2791875C (en) 2015-06-02

Similar Documents

Publication Publication Date Title
CY1123504T1 (el) Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι χρησεως αυτων
CY1122645T1 (el) Oyρεθανες, ουριες, αμιδινες και σχετικοι αναστολεις του παραγοντα χα
CY1125083T1 (el) Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου
CY1119767T1 (el) Παραγωγα πιπεριδινυλικης ινδολης και η χρηση τους ως αναστολεις του παραγοντα β του συμπληρωματος
CY1121040T1 (el) Aντιικη θεραπεια
CY1117728T1 (el) Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλ) κυκλοπροπανοκαρβοξαμιδο)-3-μεθυλπυριδιν-2-υλ)βενζοϊκου οξεος
EA201270716A1 (ru) Макроциклы в качестве ингибиторов фактора xia
CL2014000925A1 (es) Compuestos derivados de tetrahidroisoquinolina sustituidos, inhibidores del factor de coagulacion xia (fxia); composicion farmaceutica que los comprende; y su uso para el tratamiento de un trastorno tromboembolico o inflamatorio seleccionado de angina inestable, sindrome coronario agudo y fibrilacion atrial, entre otros.
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
CY1117524T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
CL2012003317A1 (es) Compuestos derivados de 5,7-dihidro-6h-pirrolo[2,3-d]pirimidin-6-ona, moduladores de la produccion de guanosin monofosfato ciclico (cmpc); su composicion farmaceutica; utiles en el tratamiento de enfermedades cardiovasculares, disfuncion endotelial y diastolica, aterosclerosis, hipertension, trombosis, angina de pecho, entre otras.
EA201391000A1 (ru) Индольные соединения или их аналоги, полезные для лечения возрастной макулярной дегенерации (amd)
EA201400729A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ СОДЕРЖАТ ГЛИТАЗОНЫ И Nrf2 АКТИВАТОРЫ
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
EA201590277A1 (ru) Дигидропиридон р1 в качестве ингибиторов фактора xia
TN2016000115A1 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
EA201590284A1 (ru) Дигидропиридон р1 в качестве ингибиторов фактора xia
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
CY1108087T1 (el) ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TAFIa
CY1119599T1 (el) Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτων
DK2105164T3 (da) Nye P2X7R-antagonister og deres anvendelse
CL2012002069A1 (es) Compuestos derivados de ácido 3-heteroarilamino-propiónico sustituido;inhibidor de proteasa catepsina a; proceso de preparacion; composicion farmaceutica; y su uso para tratar insuficiencia cardiaca, infarto de miocardio, hipertension, artritis reumatoide, asma insuficiencia renal, fobrosis quistica, bronquitis cronica, trombosis, dolor.

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment